אגיסטן לכסניות
padagis israel agencies ltd, israel - clotrimazole - לכסניה - clotrimazole 10 mg - clotrimazole
בינוקריט 8000 יחבל 0.8 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin
טפינלר 50 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib
טפינלר 50 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 50 mg - dabrafenib
טפינלר 75 מג
novartis israel ltd - dabrafenib as mesilate - קפסולה קשיחה - dabrafenib as mesilate 75 mg - dabrafenib
מקיניסט 0.5 מג
novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 0.5 mg - trametinib
מקיניסט 2 מג
novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib
רקורמון 2000 iu
roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
רקורמון iu 3000
roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
רקורמון iu 5000
roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative